One injection protects preterm babies from RSV: trial results
And with a maternal vaccine also showing potential, there's hope for conquering the infection, an expert commentator says
A single intramuscular injection of the monoclonal antibody nirsevimab reduces respiratory syncytial virus (RSV) infection in pre-term infants by 70% compared with placebo, trial results show.
In the trial, more than 1400 babies born between 29 weeks and 34 weeks and six days were randomised in a two-to-one ratio to a 50mg nirsevimab injection or placebo saline injection, respectively.
The babies, at 164 sites across 23 countries including Australia, received their injections in the two months prior
